Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 28, 2017; 23(32): 5875-5886
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875
Study ID | Setting | Study drugs | Phase | Status |
NCT01964430 | Adjuvant | Nab-paclitaxel + Gemcitabine vs Gemcitabine | III | Recruiting |
NCT02506842 | Adjuvant | Nab-paclitaxel + Gemcitabine vs OFF | III | Recruiting |
NCT02023021 | Adjuvant | Nab-paclitaxel + Gemcitabine | II | Recruiting |
NCT02125136 | Neoadjuvant | Nab-paclitaxel + Gemcitabine vs FOLFIFINOX | II | Recruiting |
NCT02243007 | Neoadjuvant | Nab-paclitaxel + Gemcitabine vs FOLFIFINOX | II | Recruiting |
NCT02717091 | Neoadjuvant/borderline resectable | Nab-paclitaxel + Gemcitabine vs FOLFIFINOX | II | Recruiting |
NCT02481635 | NEO/adjuvant | Nab-paclitaxel + Gemcitabine + radiotherapy | I-II | Recruiting |
NCT01431794 | Neoadjuvant | Nab-paclitaxel + Gemcitabine + LDE-225 | I-II | Active not recruiting |
NCT02588443 | NEO/adjuvant | Nab-paclitaxel + Gemcitabine + RO7009789 | I | Recruiting |
NCT02272738 | Neoadjuvant | Nab-paclitaxel + Gemcitabine + radiotherapy | I | Recruiting |
NCT02506803 | Neoadjuvant | Nab-paclitaxel + Gemcitabine | I | Recruiting |
NCT02427841 | Resectable | Nab-paclitaxel + Gemcitabine followed by radiotherapy | II | Recruiting |
NCT02550327 | Resectable | Nab-paclitaxel + Gemcitabine + Cisplatin + Anakinra | I | Recruiting |
NCT02210559 | Locally advanced | Nab-paclitaxel + Gemcitabine + FG-3019 | I-II | Recruiting |
NCT02394535 | Locally advanced | Nab-paclitaxel + Capecitabine + radiotherapy | I | Recruiting |
NCT02124369 | Borderline unresectable | Nab-paclitaxel + Gemcitabine | II | Recruiting |
NCT02043730 | Unresectable locally advaced | Nab-paclitaxel + Gemcitabine | II | Recruiting |
NCT02207465 | Unresectable locally advanced | Nab-paclitaxel + Gemcitabine + radiotherapy | I | Recruiting |
NCT02272738 | Unresectable locally advanced | Nab-paclitaxel + Gemcitabine | I | Recruiting |
NCT01978184 | Preoperative | Nab-paclitaxel + Gemcitabine + Hydroxychloroquine | II | Recruiting |
NCT02427841 | Preoperative | Nab-paclitaxel + Gemcitabine + radiotherapy | II | Recruiting |
NCT02723331 | Preoperative | Nab-paclitaxel + Gemcitabine followed by SBRT | II | Recruiting |
NCT02930902 | Preoperative | Nab-paclitaxel + Gemcitabine + Pembrolizumab + Paricalcitol | I | Recruiting |
- Citation: Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886
- URL: https://www.wjgnet.com/1007-9327/full/v23/i32/5875.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i32.5875